JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW FAR 13.106-1

(OVER MICRO-PURCHASE THRESHOLD($3.5K) BUT NOT EXCEEDING THE SAT ($150K))

IAW FAR13.104, COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW FAR13.106-1(b), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW FAR13.106-3(b)(3),COs are required to include additional statements ***explaining the absence of competition*** (see 13.106-1 for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW FAR13.106-3(b)(3). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

1. ACQUISITION PLAN ACTION ID:	**1A. PROJECT/TASK No.**	**1B. ESTIMATED AMOUNT:**
VA250-16-AP-4295	539-16-3-043-0109	[redacted]

2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:

The bioMerieux Vitek 2 fully automated identification and susceptibility testing instrument meets the performance characteristics for accuracy and precision as defined by the 1988 Clinical Laboratory Improvement Act (CLIA) and the Clinical and Laboratory Standards Institute (CLSI). The Vitek 2 is approved by the Food and Drug Administration (FDA). BioMerieux, Inc. shall propose the suggested/recommended reagents/consumables that meet the requirements of the facility.

3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:

The bioMerieux Vitek 2 instrument provides the highest level of accuracy in identification and susceptibility results, the most diverse range of antibiotics on the susceptibility panels, and the most complete database with the highest number of organisms definitively identified to species level. The bioMerieux Vitek 2 is unique in several features. In addition, the Vitek 2 is the only platform available to I.D. Anaerobic organisms.

The Vitek 2 instrument requires smaller test volumes (infectious material), and smaller volumes of chemical reagents than other available instruments. All biohazardous and chemical materials used in the identification and susceptibility testing process are automatically sealed in small plastic test cards. The system generates 30 – 50% less biohazardous and chemical waste than other systems and reduces waste disposal costs of the institution.

The Vitek 2 is the only FDA-approved instrument that uses advanced colorimetry identification technology that can provide identification of bacterial isolates in 3 hours, reducing the turn-around-time of results to providers and enhances patient care.

The Vitek 2 system includes an Advanced Expert System (AES) that analyzes MIC patterns and detects phenotypes for most organisms tested. This optimizes laboratory efficiency for lean laboratory management. Rapid MIC results allow providers to discontinue empiric antibiotic therapy and prescribe targeted therapy, resulting in improved patient outcomes.

4. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:

For FSS, the requirement for a synopsis is waived based upon FAR 5.202(11). Also see 8.404(a).